Kalaris Therapeutics, Inc.(KLRS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
KLRS Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Kalaris Therapeutics, Inc. (KLRS), a Healthcare sector company. KLRS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of KLRS by reported 13-F value include Samsara BioCapital, RTW INVESTMENTS, Alyeska Investment Group, L.P., based on the most recent SEC filings. KLRS trades on the Nasdaq exchange and files with the SEC under CIK 1754068. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KLRS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kalaris Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-11.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+37.2% YoYOperating Income
+10.8% YoYEPS (Diluted)
+94.5% YoYTotal Assets
+1875.6% YoYOp. Cash Flow
-85.6% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-43.4M +37.2% | $-69.2M +63.7% | $-190.4M -12.9% | $-168.7M +1.9% | $-172.0M -146.4% | $-69.8M |
| Operating Income | $-46.2M +10.8% | $-51.7M +74.1% | $-199.9M -16.8% | $-171.2M -0.8% | $-169.8M -138.1% | $-71.3M |
| EPS (Diluted) | $-2.85 +94.5% | $-51.77 -23.0% | $-42.09 -1813.2% | $-2.20 +19.7% | $-2.74 | — |
| Total Assets | $121.7M +1875.6% | $6.2M -96.8% | $190.8M -31.1% | $277.1M -3.3% | $286.6M -22.7% | $370.8M |
| Operating Cash Flow | $-38.4M -85.6% | $-20.7M +83.4% | $-124.5M +12.4% | $-142.1M -33.6% | $-106.3M -74.8% | $-60.8M |
| Free Cash Flow | $-38.6M | — | — | — | $-106.3M -74.2% | $-61.0M |
Get alerted when KLRS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Kalaris Therapeutics, Inc. including:
Top Institutional Holders of KLRS
Samsara BioCapital, LLC
$52.4M12,881,175 shRTW INVESTMENTS, LP
$5.3M1,300,000 shAlyeska Investment Group, L.P.
$2.3M572,687 shSiren, L.L.C.
$1.8M435,798 shVANGUARD CAPITAL MANAGEMENT LLC
$1.6M398,712 shIkarian Capital, LLC
$1.5M360,000 shUBS Group AG
$1.1M262,131 shRENAISSANCE TECHNOLOGIES LLC
$607.9K149,351 shMARSHALL WACE, LLP
$566.5K139,201 shGEODE CAPITAL MANAGEMENT, LLC
$464.3K114,037 sh
| Fund | Value | Shares |
|---|---|---|
| Samsara BioCapital, LLC | $52.4M | 12,881,175 |
| RTW INVESTMENTS, LP | $5.3M | 1,300,000 |
| Alyeska Investment Group, L.P. | $2.3M | 572,687 |
| Siren, L.L.C. | $1.8M | 435,798 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.6M | 398,712 |
| Ikarian Capital, LLC | $1.5M | 360,000 |
| UBS Group AG | $1.1M | 262,131 |
| RENAISSANCE TECHNOLOGIES LLC | $607.9K | 149,351 |
| MARSHALL WACE, LLP | $566.5K | 139,201 |
| GEODE CAPITAL MANAGEMENT, LLC | $464.3K | 114,037 |
More Healthcare Companies
View all Healthcare →Put KLRS on your watchlist
Track score changes the day Kalaris Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KLRS a good stock to buy?
13F Pro's AI-powered analysis of Kalaris Therapeutics, Inc. (KLRS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KLRS are available on the KLRS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KLRS is classified as a small company.
Which hedge funds own KLRS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KLRS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kalaris Therapeutics, Inc.'s investment landscape.